Alamar Biosciences (ALMR)

• Market cap: $2.13B
• 1 day: 3.26%
• 5 days: 20.92%
• 1 month: -4.51%
• 3 months: 18.54%
• 6 months: 26.45%
• Year to date: 39.5%
• 1 year: 39.5%
• 5 years: 39.5%
• 10 years: 39.5%
• Sector: Healthcare
• Industry: Medical Devices

About: Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.